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Background & aims: Recent studies have suggested that the gut microﬂora has metabolic effects. We
aimed to evaluate postnatal growth in preterm infants who received different probiotic supplements,
and to assess the safety of probiotic administration.
Methods: This prospective, randomized, double-blind, controlled trial was performed at three tertiary
care neonatal units. Preterm infants were randomly assigned to receive daily supplementation over 4e6
weeks with placebo (group C) or probiotics (group P). Group P comprised three subgroups: P1 received
Biﬁdobacterium lactis, P2 received Biﬁdobacterium longum, and P3 received B. lactis and B. longum. We
assessed postnatal growth during the supplementation period and up to a corrected gestational age (GA)
of 41 weeks when body composition was assessed using whole-body dual-energy X-ray absorptiometry.
Aerobic and anaerobic blood cultures were performed on suspicion of late-onset sepsis.
Results: The study comprised 199 preterm infants with a mean GA of 29.1 ± 1.4 weeks and a mean birth
weight of 1173 ± 210 g, who received a placebo (group C, n ¼ 52) or probiotics (group P, n ¼ 147) from the
ﬁrst week of life. At the end of the supplementation period, no statistically signiﬁcant differences were
seen between the groups in relation to the mean body weight (group C ¼ 1906 ± 23 g, group
P ¼ 1875 ± 14 g, p ¼ 0.25), length, or head circumference. The incidence rates of necrotizing enterocolitis
and late-onset sepsis were similar in the two groups. At the corrected GA of 41 weeks, there were no
differences between the groups with respect to anthropometric measurements or body composition
analysis.
Conclusions: Preterm infants receiving Biﬁdobacterium supplements did not exhibit better postnatal
growth compared with those who received placebo treatment. No adverse effects were associated with
probiotic administration.
Registered under ClinicalTrials.gov Identiﬁer no. NCT01379417.
Crown Copyright © 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ES, day at the end of supplementation; DEXA, dual energy X-ray absorptiometry; GA, gestational age; HC, head
reat; NEC, necrotizing enterocolitis; PCR, polymerase chain reaction; PP, per protocol; SD, standard deviation; TT,
e-la-Vallee, France) and Nestec (Vevey, Switzerland).
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Optimal postnatal growth is essential for very low birth weight
(VLBW) infants. Indeed, extra-uterine growth restriction is related
to complications associated with prematurity and to deﬁcits in
nutrient intakes. Recent studies have suggested that aggressive
nutritional support can help to reduce weight and length deﬁcits
upon discharge from hospital [1].
Probiotics, including Biﬁdobacterium, signiﬁcantly reduce the
incidence of necrotizing enterocolitis (NEC) and mortality rates in
VLBW infants [2]. Furthermore, a positive effect on weight gain has
been reported in rapidly growing animals [3], which could be
associated with the metabolic effects of probiotics [4]. Some au-
thors have even suggested that there might be a relationship be-
tween the composition of the gut microﬂora and a later risk of
obesity in adults [5]. In a previous observational study, we reported
a relationship between the diversity of the intestinal microbiota
and weight gain in VLBW infants [6]. Kitajima et al. suggested that
supplementation with Biﬁdobacterium breve might improve
gastrointestinal tolerance and weight gain in VLBW infants colo-
nized with B breve [7]. Biﬁdobacterium lactis has been shown to
evoke a similar effect in term infants [8]. Reports suggest that full
enteral feeding might be achievable earlier in preterm infants who
receive supplements of Lactobacillus sporogenes alone [9], a mixture
of Lactobacillus GG and bovine lactoferrin [10], a combination of
strains of Biﬁdobacterium species [11], or a combination of Biﬁdo-
bacterium and Lactobacillus acidophilus [12]. Randomized,
controlled trials that consider weight gain as the main outcome are
scarce, and none of these studies showed an improvement in
weight gain [2]. The probiotic supplements used in these studies
included Lactobacillus [9,13] and Saccharomyces boulardii [14], but
not Biﬁdobacterium.
The primary objective of this study was to evaluate the effect of
Biﬁdobacterium supplementation on short-term postnatal growth
and body composition in VLBW infants, and its secondary objective
was to assess the safety of probiotic administration.
2. Subjects and methods
2.1. Study design
This was a multicenter, double-blind, randomized, placebo-
controlled trial that compared two groups of patients treated
with probiotics or a placebo.
2.2. Population
Preterm infants who were hospitalized at French tertiary care
centers in Lyon, Montpellier, and Bron, were eligible to participate
in the study if theymet the following criteria: a gestational age (GA)
at birth of between 25 weeks and 31 weeks, a birth weight of be-
tween 700 g and 1600 g that was appropriate for the GA according
to Usher's reference growth curves, admission to a participating
unit within seven days of life, enteral feeding initiated before the
ﬁfth day of life, and the receipt of written parental consent. Infants
were not eligible to participate in the study if they presented with
NEC at stage 1B [15], a severe malformation or any gastrointes-
tinal malformations, or a severe medical or surgical condition.
Furthermore, infants were not eligible to participate if their
mothers had not been administered antenatal steroids or if their
parents lived at too great a distance from the participating center to
attend the follow-up visits. Participating infants were subsequently
excluded from the study if any of the following occurred: an
interruption of enteral or oral feeding for more than 72 h caused bysevere gastrointestinal disorders, including Bell's stage NEC  2A
[15], major gastrointestinal surgery, a conﬁrmed or suspected
intolerance to cow's milk, prompting the use of protein-hydrolyzed
formula, or the withdrawal of parental consent.2.3. Interventions
The preterm infants received one capsule daily that contained
either probiotics plus maltodextrin if they were in the probiotics
group (group P), or maltodextrin alone if they were in the control
group (group C). The intervention was blinded, because the pow-
ders within the capsules were similar in color and appearance.
Three probiotic mixtures were used: group P1 received B. lactis,
group P2 received B. longum, and group P3 received B. lactis and
B. longum. The quantity of probiotics administered was 109 colony-
forming units/d, which was similar to that used in the ﬁrst ran-
domized, controlled trial [16]. Each capsule contained 250 mg of
powder, which was dissolved in 1 mL of sterile water at the bedside
and was administered by nurses at the beginning of the midday
feed. Quality control of the capsules was performed every six
months during the study. Infants started to receive the supplement
before the end of the ﬁrst week of life, and they continued to
receive the supplement for four weeks if their GA at birth was 29
weeks or for six weeks if their GA at birth was28 weeks. Duration
of intervention depended on GA because we aimed to evaluate
probiotic supplementation during a minimal 4 weeks period, and 2
weeks more in younger babies in whom it is relevant to assess
postnatal growth over a longer period.
The participants, care providers, and those assessing patient
outcomes were blinded to the interventions administered.2.4. Number of subjects
The sample sizewas calculated to permit the detection of a 150 g
difference in body weight at the end of the intervention period
between the placebo and the pooled probiotics groups, which is
less than the 200 g difference in body weight reported by Kitajima
et al. [7], with a randomization ratio of 1:3, a power of 90%, and an
a-error of 5%. Assuming an early termination rate of 10%, we
planned to include 50 subjects in group C and 150 subjects in group
P. With an early termination rate of 20%, the sample size allowed
the detection of a 180 g difference in body weight between the
placebo and pooled probiotics groups, with a power of 90%.2.5. Randomization and group allocation
Infants were assigned to their treatment groups according to a
pre-established randomization list that was stratiﬁed according to
the investigating center and the GA at birth (28 weeks or 29
weeks), with a block size of four. Two treatment groups were
deﬁned, the control group (group C) and the probiotics group
(group P), with the latter being composed of three subgroups (P1,
P2, and P3). Each patient was randomized to one of the four
treatment groups (C, P1, P2, or P3) with a 1:1:1:1 ratio within each
center and stratum, leading to a 1:3 randomization in relation to
group C and group P, which formed the focus of the primary
analysis. The 1:3 randomization ratio in favor of group P was
justiﬁed by the known protective effect of probiotics against NEC in
preterm infants [16]. The randomization sequence was generated
by CK using PROC PLAN with SAS® version 9.1 (SAS Institute Inc.,
Cary, NC, USA). Patients were allocated to receive the different
treatments using consecutively numbered, sealed, opaque enve-
lopes for each center and stratum.
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Feeding practices were standardized across the centers. Paren-
teral feeding was provided until an enteral intake of 100e120 mL/
kg$d Pasteurized human milk (HM) (donor milk or own mother's
milk), was administered until the infant weighed 1500 g. Human
milk was enriched with 4 g of Eoprotine® powder (Milupa, France)
per 100 mL of HM. If the mother did not produce sufﬁcient milk, a
preterm formula (Pre Nidal, Nestle France, Marne-la-Vallee, France)
was provided, either in addition to the HM or alone. The preterm
formula provided 80 kcal and 2.3 g protein per 100 mL, and was
packaged in ready-to-use 90 mL bottles that were delivered to the
hospital. When the infants were discharged fromhospital, Pre Nidal
was provided to the families until the study ended at a corrected GA
of 41 weeks.
2.7. Study schedule and outcome assessment
Visits were planned on the day of inclusion into the study (day
1), on day 21, on the day at the end of the supplementation period
(DES), which was day 28 or day 42, and at the end of the study's
theoretical term (TT).
2.7.1. Growth and body composition
The primary efﬁcacy variable was the body weight measured
on the DES. Growth was also assessed by calculating the increase
in body weight (g/kg$d), length (cm/wk), and head circumference
(HC) (cm/wk) during this period. Weight for length, weight for
age, length for age, and HC for age Z-scores, and changes from
baseline Z-scores were calculated at birth, upon study inclusion,
on the DES, at discharge, and at the end of the study's TT, using
Olsen's reference curves [17]. At a corrected GA of 41 weeks, a
whole-body dual-energy X-ray absorptiometry (DEXA) scan
(Hologic QDR 4500A, Infant WB software; Hologic Inc., Waltham,
MA, USA) was performed to assess bone mineral content, soft
tissue composition. As the study took place in three different
units, quality control of the bone mineral content and soft tissue
measurements was carried out using our all-solid DEXA phantoms
[18,19].
2.7.2. Nutrient intakes and gastrointestinal tolerance
Enteral and parenteral intakes were prospectively recorded
daily, allowing the calculation of total daily energy (kcal/kg$d) and
protein (g/kg$d) intakes. The occurrence of NEC at Bell's stage 2
was recorded. A gastrointestinal tolerance score, based on daily
records of regurgitations, vomiting, gastric residuals, numbers of
stools, and abdominal distension, was calculated as previously
described [6].
2.7.3. Stool analyses
On day 21 of the supplementation schedule, the composition of
the gut microbiota was determined for all infants using the poly-
merase chain reaction (PCR) temporal temperature gradient gel
electrophoresis method. This method, which uses a non-selective
PCR ampliﬁcation of the V3 hypervariable region of the 16S ribo-
somal ribonucleic acid gene, which is conserved among eubacteria,
to determine the number and nature of the different taxonomic
units present in a sample, has been compared previously with a
conventional culture method for the analysis of gut microbiota in
neonates [20]. The number of different taxonomic units, or the
diversity index, reﬂects the diversity of the microbiota in each
patient [6]. We measured fecal calprotectin on day 21, using an
enzyme-linked immunosorbent assay (Bühlmann Laboratories AG,
Sch€onenbuch, Switzerland).2.7.4. Blood cultures
Whenever late-onset sepsis was suspected, two blood samples
(1 mL) were drawn for aerobic and anaerobic blood cultures to
assess the safety of the probiotic supplementation.
2.8. Data collection and management
Nurses collecting the data, the doctors involved in the follow-up,
and attending physicians were blinded with respect to which
intervention groups the infants had been allocated. Parental char-
acteristics and antenatal data were extracted from the infants'
medical records. Body weights were recorded daily, and crown-
heel lengths and HC were recorded from the time the infants
were included in the study to the time of their discharge from the
hospital at the TT using an electronic diary.
2.9. Statistical analysis
Three populations were deﬁned for analysis. The population in
which the primary efﬁcacy analysis was undertaken was the
intention-to-treat (ITT) population, which was deﬁned as the group
of patients who were administered at least one dose of the placebo
or probiotic and were assessed at least once while they were being
treated. The conﬁrmatory per protocol (PP) populationwas deﬁned
as the subset of the ITT population that was not subject to any
major protocol deviations. Major deviations, deﬁned a priori before
the study was unblinded, comprised the administration of any
probiotic before study inclusion, any randomization error or error
in the administration of treatment, treatment compliance that was
80% (i.e. study capsules not administered for at least four days to
patients with a GA at birth of 28 weeks or for at least six days to
patients with a GA at birth of 29 weeks), probiotics not being
administered for more than three consecutive days, and no weight
assessment on the DES. Any other protocol deviation was consid-
ered to be minor. The third analysis set was the safety population,
which was deﬁned as infants who had received at least one dose of
the placebo or probiotic and fromwhom safety data were collected.
The results were analyzed by a statistician who was blinded to
the treatment allocation, using SAS 9.2 (SAS Institute Inc., Cary, NC,
USA) for Windows. Statistical tests were two-sided and conducted
at the 5% level. Bonferroni corrections for multiplicity were planned
in case of a signiﬁcant global treatment effect conditioning analyses
of the effect of the three subgroups of probiotics as planned in the
protocol. It was emphasized, subsequently to the design of this
study, that probiotics cannot be studied as a whole and that any
positive or negative effects on the selected outcome should be
investigated in relation to each probiotic species [21]. Hence, we
provide descriptive results for each of the three probiotic sub-
groups (i.e. P1, P2, and P3) even if no global treatment effect was
found.
Anthropometric measurements (weight, height, and HC) were
analyzed using ﬁxed-effect analyses of covariance (ANCOVAs) with
the baseline values of the parameters of interest, namely, the mean
daily protein intakes, mean daily energy intakes, and gender, as
covariates, and gender, the randomization stratum, that is, a GA of
28weeks or a GA of29weeks, and the treatment group (placebo
or pooled probiotics) as ﬁxed effects (ANCOVA Model 1).
A conﬁrmatory analysis was undertaken on the PP population.
Post-hoc conﬁrmatory ANCOVAs were performed, which accoun-
ted for the intake of HM and the number of days onwhich antibiotic
treatment was administered during the supplementation period
(ANCOVA Model 2).
Mean daily energy and protein intakes during the supplemen-
tation period were analyzed using ﬁxed-effect ANCOVA models
using the subjects' weights at baseline as covariates, and with
Fig. 1. Study ﬂow chart. The probiotics subgroup P1 was administered Biﬁdobacterium lactis, P2 was administered Biﬁdobacterium longum, and P3 was administered B. lactis and
B. longum. ITT, Intention to treat; PP, Per protocol; DES, Day at the end of supplementation.
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ﬁxed effects. It was emphasized subsequent to the design of this
study, that probiotics cannot be studied as a whole and that any
positive or negative effects on the selected outcome should be
investigated in relation to each probiotic species [21]. Hence, we
provide descriptive results for each of the three probiotic sub-
groups (i.e. P1, P2, and P3).
2.10. Ethics
The study was conducted in accordance with French regulations
and the Helsinki Declaration of 1975 that was revised in 1983. The
protocol was approved by the lead center's ethics committee (CPP
Sud Mediterranee IV) and by the French National Agency for Medi-
cines and Health Products Safety, and it was registered on
ClinicalTrial.gov (NCT01379417).
3. Results
Between November 2007 and June 2010, 199 infants with a
mean ± standard deviation (SD) age of 6.4 ± 1.5 days were included
in the study (Montpellier: 78, Lyon: 65, and Bron: 56). Forty (20.3%)
subjects discontinued the study prematurely and, of these, 11
(21.2%) infants were in group C and 29 (20%) infants were in group P
(Fig. 1).
The mean duration of hospitalization was 50.4 ± 17.4 days,
which was similar for both treatment groups. The reasons for
discharge from the participating centers were similar for the two
treatment groups: 63.3% of infants were discharged to their homes,
24.2%were transferred to other hospital, and six (3.0%) infants died.
The remaining 19 (9.5%) subjects stayed in hospital when the study
ended at a corrected GA of 41 weeks. Subjects in group C received a
mean of 32.3± 7.0 capsules and subjects in group P received amean
of 31.0 ± 9.9 capsules, which corresponded to a mean rate of
compliance of 94.5 ± 12.7% and 90.4 ± 23.3%, respectively.
The population characteristics of groups C and P were similar
(Table 1). Half of the neonates were very immature with a GA of
28 weeks.Table 1
Characteristics of the very low birth weight infants (n ¼ 197, representing the
intention-to-treat population) who received either a placebo or a probiotic
supplement.
Control group
(n ¼ 52)
Probiotic group
(n ¼ 145)
Pregnancy/Delivery
Cesarean section (%) 75 79.3
Per-partum antibiotics (%) 53.8 39.6
At birth
GA (wk) 29.4 (27.9; 30.6) 29.0 (28.1; 30.1)
BW (g) 1170 (1055; 1370) 1170 (1000; 1320)
Male gender (%) 67.3 45.8
Z-score for BW 0.36 (0.88; 0.09) 0.38 (0.90; 0.05)
Since birth
Surfactant (%) 63.5 59.3
PDA requiring treatment (%) 19.2 13.8
Assisted ventilation (%) 50 52.4
IVH or PVL (%) 15.4 9
At study inclusion
Postnatal age (days) 7.0 (5; 8) 7.0 (6; 8)
Body weight (g) 1085 (968; 1295) 1090 (930; 1196)
Assisted ventilation (%) 9.6 11
Antibiotics (%) 9.6 9.7
The data are presented as % for categorical parameters and as medians (Q1; Q3) for
continuous variables. BW: birth weight; GA: gestational age; IVH: intraventricular
hemorrhage; PDA: patent ductus arteriosus; PVL: periventricular hemorrhage.Parenteral nutrition was administered to 81.2% of the subjects
with a mean volume of 91.6 ± 33.2 mL/kg$d administered at in-
clusion, which corresponded to a mean intake of 11.3 ± 4.5 g/kg$d
of carbohydrates, 1.4 ± 0.8 g/kg$d of lipids, and 2.5 ± 1.1 g/kg$d of
protein. Before the infants were included in the study, enteral
nutrition consisted of HM exclusively for 70.1% of the subjects, HM
with preterm formula for 29.4% of the subjects, and preterm for-
mula exclusively for one (0.5%) infant. At this time, the mean daily
enteral intake was 77.3 ± 40.7 mL/kg$d. There were no differences
in HM, energy and protein intakes between the groups during the
supplementation period (Table 2).
Gastrointestinal tolerance and the incidence of NECwere similar
in the two groups (Table 2), with the mean gastrointestinal toler-
ance score being 1.05 ± 0.36 in group C and 1.03 ± 0.39 in group P.
Poor gastrointestinal tolerance, which corresponded to a score of at
least 3, lasted for a mean period of 1.2 ± 1.7 days or 3.3 ± 4.5% of the
supplementation period in group C, and 0.9 ± 1.6 days or 3.0 ± 5.8%
of the supplementation period in group P (p ¼ 0.21 for the number
of days; p ¼ 0.26 for the percentage of days). The mean age of the
infants at which full enteral feeding was achieved was very similar
in Group C and Group P (16.6 ± 9.7 days and 15.8 ± 9.3 days,
respectively, p ¼ 0.67).
Growth during the supplementation period was similar in the
two groups (Table 3). Overall, there was no statistically signiﬁcant
difference between group C and group P in relation to the median
weight on the DES (1903 [1742e2140] g vs. 1810 [1610e1995] g,
respectively, p ¼ 0.27), but there were signiﬁcant effects associated
with the randomization stratum (p < 0.0001) and the weight at
inclusion (p < 0.0001). Similar results were obtained when the
intake of HM and the number of days onwhich antibiotic treatment
was administered during the supplementation period were
considered. Hence, there was no statistically signiﬁcant difference
between group C and group P (p ¼ 0.545), but there were signiﬁ-
cant effects associated with the randomization stratum
(p < 0.0001) and the weight at inclusion (p < 0.0001), in addition to
the mean intake of human milk (p ¼ 0.005) and the mean protein
intake (p ¼ 0.04) during the supplementation period (Table 4). No
statistically signiﬁcant difference was seen between groups C and P
with respect to the daily weight gainwhen it was averaged over the
supplementation period, either in the primary analysis
(16.6 ± 3.1 g/kg$d vs. 15.9 ± 4.1 g/kg$d, p ¼ 0.17) or in the adjusted
analysis taking the HM intake and the number of days of antibiotic
treatment into account (p¼ 0.35). Similar results were obtained for
the PP population. Likewise, there were no signiﬁcant differences
between the groups in relation to the crown-heel length or HC on
the DES. The conﬁrmatory analyses performed on the PP popula-
tion generated similar results.
At a corrected GA of 41 weeks, there were no statistically
signiﬁcant differences between the groups with regard to the
anthropometric data (Table 3), whole body mineralization, or fat
mass (Table 3). Analysis of the PP population gave similar
results.
After three weeks of treatment, the most frequently identiﬁed
microbiological families detected in the stools were, by decreasing
frequency, Staphylococcus spp., Clostridiales, Enterobacteriaceae,
and Enterococcus spp., with no differences between group C and
group P. Biﬁdobacterium spp. were more frequently identiﬁed in
subjects in group P (30.1%) than in subjects in group C (13.0%)
(p ¼ 0.04), particularly in infants who received B. lactis either alone
(34.8%) (p ¼ 0.03 compared with group C), or in combination with
B. longum (32.6%) (p ¼ 0.04 compared with group C) (Table 5). The
mean diversity scores were very similar in group C (3.4 ± 1.8) and
group P (3.4 ± 1.3) (p¼ 0.75). No statistically signiﬁcant effect of the
diversity index on daily weight gain was seen between the day of
inclusion and day 21 with theweight at inclusion, mean energy and
Table 2
Nutrition, antibiotics, and gastrointestinal tolerance during the supplementation period in very low birth weight infants (n ¼ 197, representing the intention-to-treat pop-
ulation) who received either a placebo or a probiotic supplement.
Control group
(n ¼ 52)
Probiotics group P
(n ¼ 145)
Group P1
(n ¼ 50)
Group P2
(n ¼ 48)
Group P3
(n ¼ 47)
Antibiotics, n (%) 6
(11.5)
20
(13.8)
8
(16.0)
3
(6.3)
9
(19.1)
Human milk intake (mL/kg$d) 110
(80; 130)
124
(104; 137)
126
(109; 131)
123
(109; 138)
117
(94; 143)
Days with gastrointestinal intolerancea 7
(4; 11)
7
(3; 11)
6
(3; 10)
7
(3; 11)
7
(3; 11)
NEC, n (%) 3
(5.8)
8
(5.5)
2
(4.0)
1
(2.0)
5
(10.6)
Probiotics subgroup P1 was administered Biﬁdobacterium lactis, P2 was administered Biﬁdobacterium longum, and P3 was administered B. lactis and B. longum.
The data are presented as numbers (%) or medians (Q1; Q3). NEC: necrotizing enterocolitis.
There were no statistically signiﬁcant differences between the intervention groups for any of the parameters.
a Gastrointestinal intolerance: gastrointestinal tolerance score 2.
Table 3
Growth (z-scores for body weight, length and head circumference), and body composition of very low birth weight infants (n ¼ 197, representing the intention-to-treat
population) who received either a placebo (Control) or a probiotic supplement (P).
Control
(n ¼ 52)
Probiotics (P)
(n ¼ 145)
P1
(n ¼ 50)
P2
(n ¼ 48)
P3
(n ¼ 47)
W/A z-score
A, sd 0.36[0.88; 0.09] 0.38[0.90; 0.05] 0.40[0.74;0.07] 0.40[0.91; 0.02] 0.29[1.04; 0.21]
B, sd 1.22[1.66;0.97] 1.31[1.63;0.96] 1.31[1.54;1.11] 1.36[1.68;0.95] 1.18[1.65;0.70]
C, sd 1.14[1.63;0.84] 1.35[1.72;0.98] 1.37[1.67;1.11] 1.44[1.78;1.09] 1.22[1.62;0.84]
D, sd 0.23[0.82; 0.35] 0.42[1.01; 0.24] 0.41[0.99; 0.31] 0.51[0.93; 0.24] 0.37[1.04; 0.20]
L/A z-score
A, sd 0.46[0.89; 0.10] 0.32[0.72; 0.24] 0.25[0.49; 0.27] 0.32[0.86; 0.24] 0.57[0.90; 0.20]
B, sd 0.85[1.26;0.23] 0.80[1.12;0.30] 0.81[1.04;0.40] 0.82[1.30;0.30] 0.74[1.14;0.15]
C, sd 1.57[2.25;1.08] 1.72[2.14;1.28] 1.74[2.04;1.29] 1.59[2.12;1.05] 1.78[2.62;1.32]
D, sd 1.55[1.89;1.08] 1.58[1.93;1.20] 1.50[1.93;1.23] 1.65[2.03;1.23] 1.56[1.93;0.93]
HC/A z-score
A, sd 0.08[0.70; 0.51] 0.14[0.62; 0.31] 0.10[0.42; 0.30] 0.02[0.74; 0.29] 0.18[0.62; 0.36]
B, sd 0.68[1.36;0.14] 0.76[1.24;0.34] 0.94[1.27;0.42] 0.73[1.19;0.41] 0.61[1.24;0.23]
C, sd 0.97[1.41;0.58] 1.25[1.68;0.75] 1.30[1.69;0.71] 1.31[1.70;0.78] 1.19[1.59;0.69]
D, sd 0.38[1.07; 0.12] 0.62[1.36; 0.00] 0.72[1.53;0.10] 0.65[1.50; 0.07] 0.29[0.86; 0.24]
DEXA
Fat, % 14.5[12.3; 16.2] 14.6[10.4; 18.6] 14.3[10.8; 18.8] 14.6[8.1; 17.0] 15.1[10.6; 18.1]
BMC, g 45.6[40.4; 50.9] 47.6[40.9; 51.8] 48.4[42.6; 54.0] 47.7[42.1; 50.0] 46.6[37.3; 51.3]
Probiotics subgroup P1 was administered Biﬁdobacterium lactis, P2 was administered Biﬁdobacterium longum, and P3 was administered B. lactis and B. longum.
A, at birth; B, at inclusion; C: at the end of supplementation; D, at theoretical term (41 wks corrected age); sd, standard deviation, W/A z-score, body weight-for-age z-score; L/
A z-score, length-for-age z-score, HC/A z-score, head circumference-for-age z-score; DEXA, dual-energy-x-ray absorptiometry; BMC, bone mineral content.
The data are presented as numbers (%) or medians (Q1; Q3).
There were no statistically signiﬁcant differences between the intervention groups for any of the parameters.
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randomization stratum, and treatment group as independent var-
iables. Fecal calprotectin concentrations were similar among the
different treatment groups (Control: 183[94; 268] mg/g, P: 221[104;
275] mg/g, P1: 200[126; 264] mg/g, P2: 226[91; 300] mg/g, P3: 232
[99; 275] mg/g, NS).
The incidence of bloodstream infections - assessed using both
aerobic and anaerobic blood cultures - was similar in group P and
group C (p ¼ 0.912). There were no differences in the types of
microorganisms isolated from peripheral blood samples (Table 6).
During the supplementation period, 10 (19.2%) subjects in group
C experienced 15 adverse events and 35 (24.0%) subjects in group P
experienced 45 adverse events. Possibly related adverse events
affected one (1.9%) subject in group C and ﬁve (3.4%) subjects in
group P. Two (1.4%) subjects in group P and 11 (7.5%) subjects in
group C experienced serious adverse events during the supple-
mentation period. None of these serious adverse events were
considered to be related to the study treatment. One (1.9%) subject
in group C and four (2.7%) subjects in group P died during the
supplementation period. Another subject in group P died after the
supplementation period.4. Discussion
In this population of high-risk preterm infants born in the post-
surfactant era, we did not observe any beneﬁcial effects associated
with probiotic supplementation in relation to postnatal weight
gain, neither any side-effect related to probiotic administration.
We expected that better gastrointestinal tolerance might
improveweight gain as shown by Kitajima et al. [7]. Since the study
by Kitajima et al. [7], three other studies have reported earlier
achievement of full enteral feeding [2], but this did not occur in our
study. The ﬁrst of these studies compared the effect of bovine lac-
toferrin alonewith bovine lactoferrin plus LactobacillusGG [15]. The
second study was conducted exclusively in VLBW infants whowere
fed breastmilk that was or was not supplementedwith amixture of
probiotics [12]. The third study used L sporogenes, a strain that does
not appear to have any beneﬁcial effects [9], which is in contrast to
B. lactis [2,22,23].
We previously reported a relationship between the diversity of
gut microbiota and postnatal weight gain [6], which was not
observed in our study. The proportion of infants with Biﬁdobacte-
rium in their stools was only about three-times higher in infants
Table 4
Results of the analysis of covariance (ANCOVA) and extended ANCOVA for weight at
the end of the intervention period in very low birth weight infants (n ¼ 197, rep-
resenting the intention-to-treat population) who received either a placebo or a
probiotic supplement.
ANCOVA
Model 1
ANCOVA
Model 2
p value p value
Intervention group 0.265 0.545
GA at birth <0.0001 <0.0001
Birth weight (BW) <0.0001 <0.0001
BW*RS 0.057 0.210
Mean intake during intervention:
Energy (kcal/kg$d) 0.527 0.095
Protein (g/kg$d) 0.222 0.041
Human milk (mL/kg$d) e 0.005
Gender 0.093 0.271
Days antibiotics used during intervention, n e 0.583
Weight difference at the end of intervention
probiotics-control mean, (95%CI)
30.49
(84.33, 23.66)
16.68
(70.84, 37.57)
CI: conﬁdence interval.
Results are for ﬁxed-effect analysis of covariance (ANCOVA) models with birth
weight, the mean daily intake of proteins, the mean daily energy intake, and gender
as covariates, and gender, randomization stratum, deﬁned as a gestational age of
28 weeks or  29 weeks, and intervention group (placebo or probiotics) as ﬁxed
effects (Model 1). Model 2 additionally included human milk intakes and the
number of days antibiotics were administered during the intervention as covariates.
Table 5
Gut microﬂora expressed as the proportion of infants with at least one of the 13 different
population) who received either a placebo or a probiotic supplement.
Placebo group
(n ¼ 52)
Probiotics gr
(n ¼ 145)
Staphylococcus spp., n (%) 29 (63.0) 88 (66.2)
Clostridiales, n (%) 20 (43.5) 60 (45.1)
Enterobacteriaceae, n (%) 18 (39.1) 43 (32.3)
Enterococcus spp., n (%) 16 (34.8) 45 (33.8)
Biﬁdobacterium spp., n (%) 6 (13.0) 40 (30.1)a
Acidaminococcaceae, n (%) 6 (13.0) 18 (13.5)
Streptococcus spp., n (%) 2 (4.3) 15 (11.3)
Anaerobes (various), n (%) 4 (8.7) 6 (4.5)
Burkholderiales, n (%) 2 (4.3) 6 (4.5)
Corynebacterium spp., n (%) 0 3 (2.3)
Micrococaceae, n (%) 1 (2.2) 1 (0.8)
Neisseria spp., n (%) 0 1 (0.8)
Pseudomonas spp., n (%) 1 (2.2) 0 (0.0)
Probiotics subgroup P1 was administered Biﬁdobacterium lactis, P2 was administered Biﬁ
The data are presented as numbers (%).
a p < 0.05, chi-squared test (vs placebo).
Table 6
Bloodstream infections in very low birth weight infants (n ¼ 197, representing the inten
Placebo group
(n ¼ 52)
Pr
(n
Proportion of subjects with 1 infection (%) 19
(9, 30)
17
(1
Microorganisms (%)
Coagulase-negative staphylococci, (%) 80
(55, 100)
56
(3
Staphylococcus aureus, (%) 0
(0, 0)
28
(1
Candida spp., (%) 10
(0, 29)
0
(0
Other, (%) 10
(0, 28)
16
(2
Probiotics subgroup P1 was administered Biﬁdobacterium lactis, P2 was administered Biﬁ
The data are presented as % (95% conﬁdence intervals).
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did not receive a probiotic supplement, and this difference might
have been insufﬁcient to observe a beneﬁcial effect on growth.
From our data it is not possible to explain why the proportion of
infants with BF in stools was not higher than 30% in the probiotic-
supplemented group. Further investigations are needed to evaluate
the effects of different strains and greater quantities of Biﬁdo-
bacterium and probiotic mixtures using other strains such as
lactobacillus on growth. As large randomized studies remain a
necessity to ascertain the positive effect of probiotics on NEC
incidence [21], growth should be systematically evaluated in these
studies.
The absence of any signiﬁcant differences between the groups in
relation to short-term growth could also be attributed to the use of
strains of microorganisms that are inappropriate for attaining
positive metabolic effects in these infants. Recent data suggest that
each strain exerts a distinct effect, with some strains being effective
at preventing NEC in preterm infants [22], while others are effective
at preventing and managing colic [24] or atopic diseases [25].
B. lactis reduces NEC incidence in association with other probiotics
[2,22]. A beneﬁcial effect of B. lactis on the growth of infants born to
human immunodeﬁciency virus-positive mothers has also been
suggested [8]. In preterm infants, an improvement in weight gain
that was associatedwith B breve supplementationwas reported in a
subgroup of subjects [7]. Another study reported an increasedspecies, in very low birth weight infants (n¼ 197, representing the intention-to-treat
oup Group P1
(n ¼ 50)
Group P2
(n ¼ 48)
Group P3
(n ¼ 47)
31 (67.4) 29 (65.9) 28 (65.1)
17 (37.0) 22 (50.0) 21 (48.8)
15 (32.6) 13 (29.5) 15 (34.9)
15 (32.6) 11 (25.0) 19 (44.2)
16 (34.8)a 10 (22.7) 14 (32.6)a
6 (13.0) 6 (13.6) 6 (14.0)
6 (13.0) 4 (9.1) 5 (11.6)
3 (6.5) 1 (2.3) 2 (4.7)
1 (2.2) 3 (6.8) 2 (4.7)
1 (2.2) 2 (4.5) 0
0 0 1 (2.3)
0 0 1 (2.3)
0 0 0
dobacterium longum, and P3 was administered B. lactis and B. longum.
tion-to-treat population) who received either a placebo or a probiotic supplement.
obiotics group
¼ 145)
Group P1
(n ¼ 50)
Group P2
(n ¼ 48)
Group P3
(n ¼ 47)
1, 23)
18
(7, 29)
16.7
(6, 27)
17
(6, 28)
7, 76)
67
(36, 98)
38
(4, 72)
63
(30, 97)
0, 46)
11
(0, 31)
50
(15, 85)
25
(0, 55)
, 0)
0
(0, 0)
0
(0, 0)
0
(0, 0)
, 30)
22
(0, 49)
13
(0, 36)
13
(0, 36)
dobacterium longum, and P3 was administered B. lactis and B. longum.
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subgroup of antibiotic-treated preterm infants [26]. With the
exception of our study, only four randomized, controlled studies
have analyzed weight gain as an outcome, and invariably as a
secondary outcome criterion [9,13,14]. Furthermore, two of these
studies [13] were performed over 20 years ago and on such small
numbers of infants that they cannot be considered to contribute to
the body of evidence. The other study [14] used a highly speciﬁc
probiotic (S boulardii) that cannot be used anymore because of the
reported cases of fungemia related to this microorganism [27]. The
use of L sporogenes as a probiotic has been reported, but it failed to
decrease the incidence of death, reduce the incidence of stage 2
NEC (the main outcome criterion), or to improve weight gain [9]. In
this last study, the weight gain was surprisingly low in both the
control and the probiotic groups at about 10 g/kg$d at 28 days of life
and about 12 g/kg$d at 42 days of life, and it was less than the fetal
growth rate [9]. Our study is the ﬁrst controlled randomized,
double-blind study that used weight gain as the main outcome
criterion. The effects of probiotics on weight gain may vary
depending on the species and the strains of microorganisms
employed [28].
A positive effect was expected in these rapidly growing VLBW
infants. This was based on previous reports of the effects of pro-
biotic supplementation on metabolism and growth in both animal
studies and clinical trials. In poultry, an improved weight gain was
reported in birds that received probiotic supplements during
growth [3]. The gut microbiota participates in the regulation of
energy metabolism in the host. Microbial components target
multiple systems and play key roles in metabolism, including
nutrient absorption, the maintenance of the integrity of the gut
barrier, gut hormone regulation, and fat metabolism [4]. A meta-
bolic effect associated with the gut microbiota has also been re-
ported, and a relationship between the composition of the ﬂora and
later obesity has been suggested [5]. In our population we did not
observe improved postnatal weight gain in infants who received
probiotic supplements compared with the control group. Our study
was not designed to evaluate the long-term effects of probiotics on
growth, but to assess their impact a few weeks after supplemen-
tation had ended, that is, at a corrected GA of 41 weeks. There were
no differences between the groups in relation to growth that were
determined using anthropometric parameters or body composi-
tion, as assessed by whole-body DEXA, a reference method for fat
mass assessments in neonates [29].
The absence of any signiﬁcant differences between the groups in
relation to short-term growth in our study might reﬂect a lack of
statistical power. However, this is unlikely because the number of
subjects was calculated to detect a clinically relevant [7] difference
with a power of 90%. Furthermore, we accounted for the low level
of Biﬁdobacterium implantation. Lastly, the number of infants
included in our study approached or even exceeded the numbers
included in previous nutritional studies that reported positive ef-
fects on postnatal weight gain. Our population was representative
of a typical population of preterm infants, because we also included
very immature infants who are at risk of severe growth restrictions.
The absence of effect of probiotics on short-term growth could
also be related to an insufﬁcient effect on gut microbiota in the
participating neonatal units. The proportion of infants with biﬁ-
dobacteria in stools has tripled but the basal level was low as it was
close to 10%, in agreement with our previous ﬁndings and data from
other authors [6,30]. Some authors reported higher proportions
[31,32]. It is very unlikely that we underestimated the presence of
biﬁdobacteria as the method used for stool analysis was previously
validated in neonates [20]. Our current practices (mode of delivery,
antibiotics, nutrition …) could have negatively affected the pro-
portion of infants with biﬁdobacteria in stools. However thesepractices were similar in all infants included in the study and we
were able to show a signiﬁcant - although insufﬁcient-effect of
probiotic supplementation on gut microbiota. In another setting,
such an effect might be sufﬁcient to observe an effect on growth.
Three different combinations of probiotics were tested because -
when the study was designed - there were concerns about the
different strains and mixtures of strains of probiotics. The primary
analysis was a comparison of the placebo group with the pooled
probiotics and the power calculation took into account the 1/3
randomization ratio in favor of the Probiotics. Pairwise compari-
sons were only planned in case of a signiﬁcant global effect which
was not the case. So the group Probiotic was considered as a whole.
Since we designed our study, the effect of the different strains on
NEC and death prevention was studied by different authors. Some
of them suggest that there are different effects when different
strains are used [21], others found no difference at all [33] or sug-
gested different effects when infants are supplemented with a
single or with combined strains [34]. Our a priori choice of
comparing pooled data of infants receiving different probiotic
strains to evaluate the global effect of adding probiotics when
compared to infants receiving placebo appears still legitimate.
Another limitation of this study is that any potential beneﬁcial
effects of the probiotics on growth might have been blunted by the
higher energy and protein intakes in group C.We carefully collected
data on actual energy and protein intakes during the supplemen-
tation period and took these intakes into account during the ana-
lyses, which is rarely undertaken in studies of this type. Almost all
infants received human milk, but the human milk compositionwas
not measured in our study, which could have introduced an error.
Human milk was assumed to contain 64 kcal/100 mL and 1.4 g of
protein/100 mL, which are commonly used average values. By
encoding carefully and prospectively the real amount of parenteral
ﬂuids intake and of milk intake during the study period, we mini-
mized the risk of error in nutrient's intakes calculations. However,
such an error is randomly distributed in all the feeding groups and
it is very unlikely that it could have signiﬁcant inﬂuenced our
results.
The duration of probiotic supplementation, was 4 or 6 weeks
depending on gestational age at birth to get high-quality data over a
relatively early in-hospital period. We aimed to evaluate whether
or not probiotic supplementation could support optimization of
postnatal growthwhich is required as soon as possible after birth in
very preterm infants. When the study was designed a 4 weeks-
period was shown to be efﬁcient on NEC and mortality rates and
a 6 weeks period was considered as helpful to assess a potential
effect in the more immature subjects. A recent Cochrane review
showed that there is no difference in the effect on severe NEC,
culture proven sepsis and mortality rates between studies using a
period of supplementation comprised between 4 and 6 weeks [2].
This review also suggests that probiotic supplementation until
discharge could be more efﬁcient than shorter period of supple-
mentation. Further studies on probiotics and growth in preterm
infants should evaluate such prolonged supplementation.
The optimal probiotic strains or mixtures of strains to be used in
preterm infants are not well deﬁned. One might expect that a
mixture of probiotics could help achieve beneﬁcial health effects
[2]. In our study, we did not observe any beneﬁts in the group that
received a combination of probiotics, and there was even a ten-
dency towards an increased prevalence of NEC in this group.
However, this difference was not statistically signiﬁcant possibly
due to a lack of statistical power, because our study was not
designed to investigate the effect of probiotics on NEC incidence.
Cilieborg et al. reported that preterm pigs that received amixture of
probiotics showed an increased incidence and severity of NEC that
was associated with reductions in the mucosal integrity and
S. Hays et al. / Clinical Nutrition 35 (2016) 802e811810digestive function, and an increased expression of pro-
inﬂammatory mediators [35]. In our study, fecal calprotectin, a
marker of inﬂammation, did not show an increased expression in
the infants who received a mixture of two probiotics, which raises
the possibility that the higher incidence of NEC in this group might
have been caused by a random effect. However, our results
emphasize the need for careful evaluations of different probiotic
strategies in relation to strains and doses, before they are routinely
used in preterm infants.
In conclusion, probiotics did not have a signiﬁcant effect on
gastrointestinal tolerance and short-term postnatal growth in this
study. There was no signiﬁcant difference between the two
different probiotics tested separately and no clear beneﬁt associ-
ated with using a mixture of these two probiotics. No sepsis
occurred that was related to the probiotics used for supplementa-
tion. Further studies could evaluate other strains or other symbiotic
organisms and, perhaps, different dosages to facilitate the deﬁni-
tion of the optimal probiotic mixture for NEC prevention and
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